Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 260Carcinoma, Non-Small-Cell Lung 125Glioblastoma 105Breast Neoplasms 104Ovarian Neoplasms 96Carcinoma, Hepatocellular 88Brain Neoplasms 71Rectal Neoplasms 69Neoplasm Metastasis 69Lung Neoplasms 65Colonic Neoplasms 58Neoplasms 57Glioma 52Fallopian Tube Neoplasms 44Carcinoma, Renal Cell 36Gliosarcoma 31Pancreatic Neoplasms 30Melanoma 27Liver Neoplasms 26Stomach Neoplasms 21Astrocytoma 21Adenocarcinoma of Lung 21Recurrence 20Kidney Neoplasms 19Colorectal Cancer Metastatic 17Triple Negative Breast Neoplasms 16Uterine Cervical Neoplasms 15Esophageal Neoplasms 15Sarcoma 13Prostatic Neoplasms 13

Interventions

trifluridine tipiracil drug combination 1Nivolumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Microsatellite-stable Colorectal Cancer × Bevacizumab × Clear all
NCT07011550 2026-03-20

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Suspended
7 enrolled
Gastrointestinal

Microsatellite-stable Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡